CA72-4 Detection Service

Creative Biolabs is a leading service provider that focuses on tumor-associated glycan detection. Based on our advanced platforms and extensive experience, now we provide the novel CA72-4 detection service for the diagnostic of gastric cancer for our clients all over the world.

CA72-4 in Gastric cancer

Gastric cancer (GC) is one of the most common malignant tumors in the world, ranking fifth in global incidence and third in mortality. As a gastrointestinal tumor, GC presents high recurrence and metastasis rates. In recent decades, endoscopic examination and biopsy have been served as the primary tools for the diagnostic of GC, but always limited by the high cost and invasiveness. Therefore, it is of great significance to find sensitive biomarkers for the prognosis of patients with gastric cancer.

First described in the early 1980s, CA72-4 is a novel mucin-like high molecular weight glycoprotein antigen with a molecular weight of 220 to 400 kDa. It is almost not expressed in benign tumor tissues, body fluids, and normal tissues, but its high expression can be observed in multiple cancers, including gastrointestinal tumors, pancreatic cancer, endometrial cancer, ovarian cancer, as well as gastric cancer. Research data showed that nearly 40% of GC patients have a higher level of CA72-4 and increase with the progression of the disease. Combined with carcinoembryonic antigen (CEA) and cancer antigen 19-9 (CA19-9), it can be better used for the diagnosis and prognosis of GC patients.

Fig 1. (a). Schematic illustration of the principle and procedure of the LFIA strip. (b). Magnetic intensity detected by magnetic assay reader. (Chen, 2016)

Techniques for CA72-4 Detection in Gastric Cancer

For CA72-4 detection, the total diagnostic accuracy rate of CA72-4 in detecting GC is 92.8%. What’s more, the sensitivity and specificity of CA72-4 to GC are significantly higher in patients with advanced GC than in early GC. Using a chemiluminescence kit is the easiest way to measure the level of serum CA72-4. A quantitative lateral flow immunoassay (LFIA) based on superparamagnetic nanoparticles (SPMNPs) is a rapid, sensitive, and quantitative approach for the detection of CA72-4 in human serum. The CA72-4 special monoclonal antibody is coupled onto SPMNPs to prepare the probes. After that, the intensity of the magnetic signal in the reaction zone can be quantified using a magnetization analyzer (MAR).

Creative Biolabs has been a long-term expert in the field of glycomics research. As a pioneer and the undisrupted global leader in tumor-associated glycan detection, we offer a variety of solutions to improve your productivity and streamline your research processes. If you are interested in our products or services, please do not hesitate to contact us for more detailed information.

Reference

1. Chen, Y.; et al. Rapid detection and quantification of tumor marker carbohydrate antigen 72-4 (CA72-4) using a superparamagnetic immunochromatographic strip. Analytical and bioanalytical chemistry. 2016, 408(9): 2319-2327.

Related Services:

1. CA15-3 Detection Service
2. CA125 Detection Service
3. CA19-9 Detection Service
4. Prostate-specific Antigen (PSA) Detection Service
5. CEA Detection Service
6. Mucin Detection Service